All In Biotech

Drug Trial Radar · NCT01391325

Allopurinol Outcome Study

Long-term Allopurinol Safety Study Evaluating Outcomes in Gout Patients (LASSO)

Last checked: Nov 20, 2026Latest source record: Jun 17, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

1,735

Actual

Start

Jul 2011

Primary completion

Jan 2013

Study completion Mar 2013

Sponsor

Lead sponsor
Ardea Biosciences, Inc.Industry
Sponsor type
Industry
First posted
Jul 12, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study of allopurinol in gout patients with hyperuricemia that will evaluate the safety and serum urate (sUA) lowering capability of allopurinol as a urate lowering therapy (ULT) for up to six months. Allopurinol will be dosed according to the local product label, at the discretion of the Investigator, to achieve an optimal, medically appropriate dose for each patient.

Conditions

  • Gout

Interventions

  • AllopurinolDrug

    Commercially available allopurinol 100 mg and 300 mg oral tablets will be prescribed by the Investigator according to the approved product label.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of AllopurinolTime frame: Every month for 6 months.

Locations

173 sites in 7 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Birmingham, Alabama

  • Site not named

    Bringham, Alabama

  • Site not named

    Calera, Alabama

  • Site not named

    Huntsville, Alabama

  • Site not named

    Mobile, Alabama

  • Site not named

    Chandlers, Arizona

  • Site not named

    Green Valley, Arizona

  • Site not named

    Jonesboro, Arizona

  • Site not named

    Phoenix, Arizona

  • Site not named

    Phoenix, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Anaheim, California

  • Site not named

    Carmichael, California

  • Site not named

    Covina, California

  • Site not named

    Hemet, California

  • Site not named

    Irvine, California

  • Site not named

    Los Angeles, California

  • Site not named

    Mission Viejo, California

  • Site not named

    Pasadena, California

  • Site not named

    Sacramento, California

  • Site not named

    San Diego, California

  • Site not named

    San Ramon, California

  • Site not named

    Santa Maria, California

  • Site not named

    Weslake Village, California

  • Site not named

    Denver, Colorado

  • Site not named

    Englewood, Colorado

  • Site not named

    Danbury, Connecticut

  • Site not named

    Trumbull, Connecticut

  • Site not named

    Brandenton, Florida

  • Site not named

    Brandon, Florida

  • Site not named

    Brooksville, Florida

  • Site not named

    East Brandenton, Florida

  • Site not named

    Fleming Island, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Jupiter, Florida

  • Site not named

    Miami, Florida

Showing 40 of 173 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.